Ispire Releases 2025 Financial Results: Revenue of $127.5 Million, Net Loss Widens to $39.2 Million

Sep.17.2025
Ispire Releases 2025 Financial Results: Revenue of $127.5 Million, Net Loss Widens to $39.2 Million
Ispire Technology Inc. (NASDAQ: ISPR) announced its financial results for the fiscal year ending June 30, 2025, on September 16, 2025. The report showed that the company's operating revenue was $127.5 million, down from $151.9 million in the previous fiscal year. Gross profit decreased from $29.8 million to $22.6 million, with gross profit margin falling from 19.6% to 17.8%. Net loss widened from $14.8 million to $39.2 million.

Key points:

 

·Income Decline: In the 2025 fiscal year, Ispire Technology's operating income was $127.5 million, a 16.1% decrease from the $151.9 million in the 2024 fiscal year. 

·Gross profit and gross margin decrease: Gross profit decreased from $29.8 million to $22.6 million, with the gross margin decreasing from 19.6% to 17.8%. 

·Net loss expands: The net loss expanded from $14.8 million to $39.2 million. 

·Strategic transformation: The company continues to transition from the cannabis industry to the nicotine sector.

 


 

On September 17, 2025 - According to a report on the Ispire Technology website on September 16, Ispire Technology Inc. (NASDAQ: ISPR) announced its fiscal year financial report for the period ending on June 30, 2025. The report showed that the company's revenue for the 2025 fiscal year was $127.5 million, a decrease from $151.9 million in the previous fiscal year. Gross profit decreased from $29.8 million in the previous fiscal year to $22.6 million, with a gross profit margin dropping from 19.6% to 17.8%. Net losses widened from $14.8 million in the previous fiscal year to $39.2 million. As of June 30, 2025, the company held cash and cash equivalents of $24.4 million, with operating capital of $400,000.

 

In the 2025 fiscal year, Ispire's revenue was $127.5 million, a decrease from $151.9 million in the 2024 fiscal year. This decline is primarily due to the company's strategic repositioning from the cannabis sector to the nicotine sector, despite the aim of achieving more sustainable long-term growth through this transition. Gross profit decreased from $29.8 million in the previous fiscal year to $22.6 million, with a gross margin drop from 19.6% to 17.8%. Total operating expenses increased from $43.7 million in 2024 to $60.5 million, mainly due to higher sales and marketing expenses and an increase in expected credit losses on accounts receivable.

 

The net loss expanded from $14.8 million in the 2024 fiscal year to $39.2 million in the 2025 fiscal year. This increase in loss reflects the challenges the company is facing during its strategic transformation, including increased operational expenses and declining revenues. As of June 30, 2025, the company held $24.4 million in cash and cash equivalents, with operating capital of $400,000.

 

Ispire Co-CEO Michael Wang said, "The 2025 fiscal year is a crucial period for Ispire's strategic transformation as we continue to shift our focus from the cannabis industry to the higher value nicotine industry. We have made sound strategic decisions, prioritizing quality customers over quantity, and repositioning our business for sustainable growth while prioritizing long-term partnerships. Our investments in groundbreaking technologies, including IKE Tech LLC and G-Mesh technology, are gaining favor with major tobacco companies as these innovative technologies go through regulatory approval processes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14